Rapport TherapeuticsRAPP -0.60%14 Receivables Turnover is 344.83 as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 840 Biotechnology companies, Rapport Therapeutics ranks better than 98.81% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Rapport Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $20.00 Mil. Rapport Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.06 Mil.
Hence, Rapport Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 344.83.
Rapport Therapeutics (NAS:RAPP) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Rapport Therapeutics Receivables Turnover Related Terms
Rapport Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Rapport Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RAPP vs SION, TYRA, IOVA: Receivables Turnover Comparison
For the Biotechnology subindustry, Rapport Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapport Therapeutics (RAPP) has a Receivables Turnover of 344.83 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Rapport Therapeutics and its competitors. According to the industry distribution chart, Rapport Therapeutics ranks #10 out of 840 companies in the Biotechnology industry, placing it in the top 1.2%.
Is Rapport Therapeutics' Receivables Turnover too high?
Rapport Therapeutics' current Receivables Turnover is 344.83. The Biotechnology industry median Receivables Turnover is 5.30. Rapport Therapeutics' value of 344.83 is 6406.2% above this industry median. Based on the distribution chart, Rapport Therapeutics ranks #10 out of 840 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Receivables Turnover compare to SION and TYRA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #10 out of 840 companies for Receivables Turnover. This places Rapport Therapeutics in the top 1% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.30. Rapport Therapeutics' value of 344.83 is 6406.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.30, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapport Therapeutics's current Receivables Turnover of 344.83 is 6406.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Rapport Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapport Therapeutics's current Receivables Turnover is 344.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Receivables Turnover of 344.83. The current Receivables Turnover is 344.83 and 6406.2% above the Biotechnology industry median of 5.30. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Receivables Turnover is 344.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score
Get the complete analysis for RAPP
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPP has been successfully added to your 
